{"title":"脓肿分枝杆菌对异帕米星联合疗法的抗菌药敏感性分析","authors":"Yukari Kato , Hiroaki Ihara , Satomi Takei , Ayako Nakamura , Yuichi Fujimoto , Tetsuya Handoh , Kana Kurokawa , Yuta Arai , Kohei Shibayama , Issei Sumiyoshi , Yusuke Ochi , Junko Watanabe , Kazuaki Hoshi , Shigeki Misawa , Shinsaku Togo , Toshio Naito , Yoko Tabe , Takashi Miida , Kazuhisa Takahashi","doi":"10.1016/j.jctube.2024.100464","DOIUrl":null,"url":null,"abstract":"<div><p>This study evaluated the antimicrobial potency of the combination of isepamicin (ISP) for <em>Mycobacterium abscessus</em> species (MABS). 34 clinical MABS strains were isolated from clinical samples. Of them, 11 (32.4 %) were <em>M. abscessus</em> subsp. <em>abscessus</em> (Mab), 22 (64.7 %) were <em>M. abscessus</em> subsp. <em>massiliense</em> (Mma), and one (2.9 %) was <em>M. abscessus</em> subsp. <em>bolletii</em> (Mbo). We compared susceptibility to sitafloxacin (STFX)-ISP and clarithromycin (CLR)-ISP combinations with those of the antimicrobial agents alone, and synergistic effects were observed in 41.2 % and 17.6 % when treated with STFX-ISP and CLR-ISP. By hierarchical cluster analysis, the isolates divided into treatment-sensitive and treatment-resistant groups. Non-Mma or rough colony isolates were significantly likely to belong to the treatment-sensitive group (p = 0.024, p < 0.001, respectively). These results suggest that the ISP-containing combination could be a new therapeutic strategy for MABS, especially in cases of non-Mma: treatment-refractory subspecies, and rough morphotypes: high-virulence morphotypes.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"36 ","pages":"Article 100464"},"PeriodicalIF":1.9000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579424000512/pdfft?md5=b7ba95048e11d7c35e4529da77e36cba&pid=1-s2.0-S2405579424000512-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Antimicrobial susceptibility analysis of isepamicin combination treatments in Mycobacterium abscessus species\",\"authors\":\"Yukari Kato , Hiroaki Ihara , Satomi Takei , Ayako Nakamura , Yuichi Fujimoto , Tetsuya Handoh , Kana Kurokawa , Yuta Arai , Kohei Shibayama , Issei Sumiyoshi , Yusuke Ochi , Junko Watanabe , Kazuaki Hoshi , Shigeki Misawa , Shinsaku Togo , Toshio Naito , Yoko Tabe , Takashi Miida , Kazuhisa Takahashi\",\"doi\":\"10.1016/j.jctube.2024.100464\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This study evaluated the antimicrobial potency of the combination of isepamicin (ISP) for <em>Mycobacterium abscessus</em> species (MABS). 34 clinical MABS strains were isolated from clinical samples. Of them, 11 (32.4 %) were <em>M. abscessus</em> subsp. <em>abscessus</em> (Mab), 22 (64.7 %) were <em>M. abscessus</em> subsp. <em>massiliense</em> (Mma), and one (2.9 %) was <em>M. abscessus</em> subsp. <em>bolletii</em> (Mbo). We compared susceptibility to sitafloxacin (STFX)-ISP and clarithromycin (CLR)-ISP combinations with those of the antimicrobial agents alone, and synergistic effects were observed in 41.2 % and 17.6 % when treated with STFX-ISP and CLR-ISP. By hierarchical cluster analysis, the isolates divided into treatment-sensitive and treatment-resistant groups. Non-Mma or rough colony isolates were significantly likely to belong to the treatment-sensitive group (p = 0.024, p < 0.001, respectively). These results suggest that the ISP-containing combination could be a new therapeutic strategy for MABS, especially in cases of non-Mma: treatment-refractory subspecies, and rough morphotypes: high-virulence morphotypes.</p></div>\",\"PeriodicalId\":37942,\"journal\":{\"name\":\"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases\",\"volume\":\"36 \",\"pages\":\"Article 100464\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-07-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2405579424000512/pdfft?md5=b7ba95048e11d7c35e4529da77e36cba&pid=1-s2.0-S2405579424000512-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405579424000512\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405579424000512","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Antimicrobial susceptibility analysis of isepamicin combination treatments in Mycobacterium abscessus species
This study evaluated the antimicrobial potency of the combination of isepamicin (ISP) for Mycobacterium abscessus species (MABS). 34 clinical MABS strains were isolated from clinical samples. Of them, 11 (32.4 %) were M. abscessus subsp. abscessus (Mab), 22 (64.7 %) were M. abscessus subsp. massiliense (Mma), and one (2.9 %) was M. abscessus subsp. bolletii (Mbo). We compared susceptibility to sitafloxacin (STFX)-ISP and clarithromycin (CLR)-ISP combinations with those of the antimicrobial agents alone, and synergistic effects were observed in 41.2 % and 17.6 % when treated with STFX-ISP and CLR-ISP. By hierarchical cluster analysis, the isolates divided into treatment-sensitive and treatment-resistant groups. Non-Mma or rough colony isolates were significantly likely to belong to the treatment-sensitive group (p = 0.024, p < 0.001, respectively). These results suggest that the ISP-containing combination could be a new therapeutic strategy for MABS, especially in cases of non-Mma: treatment-refractory subspecies, and rough morphotypes: high-virulence morphotypes.
期刊介绍：
Journal of Clinical Tuberculosis and Mycobacterial Diseases aims to provide a forum for clinically relevant articles on all aspects of tuberculosis and other mycobacterial infections, including (but not limited to) epidemiology, clinical investigation, transmission, diagnosis, treatment, drug-resistance and public policy, and encourages the submission of clinical studies, thematic reviews and case reports. Journal of Clinical Tuberculosis and Mycobacterial Diseases is an Open Access publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
